KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) Financial Ratios
6 years of historical data (2020–2025) · Healthcare · Medical - Instruments & Supplies
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
4.81
↓-17% vs avg
5yr avg: 5.80
30Y Low5.8·High5.8
ROE
↑
-55.4%
↓+92% vs avg
5yr avg: -677.4%
30Y Low-55%·High-55%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
KMTS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
KESTRA MEDICAL TECHNOLOGIES, LTD. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Market Cap | $1.2B | $1.2B | — | — | — | — |
| Enterprise Value | $970M | $998M | — | — | — | — |
| P/E Ratio → | -3.88 | — | — | — | — | — |
| P/S Ratio | 19.44 | 19.92 | — | — | — | — |
| P/B Ratio | 4.81 | 5.80 | — | — | — | — |
| P/FCF | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
KMTS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 16.69 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — |
KMTS Profitability
Margins and return-on-capital ratios measuring operating efficiency
KESTRA MEDICAL TECHNOLOGIES, LTD. earns an operating margin of -177.8%. Operating margins have expanded from -1054.0% to -177.8% over the past 3 years, signaling improving operational efficiency. A negative ROE of -55.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Gross Margin | 40.5% | 40.5% | 1.3% | -139.6% | — | — |
| Operating Margin | -177.8% | -177.8% | -305.8% | -1054.0% | — | — |
| Net Profit Margin | -190.3% | -190.3% | -338.4% | -1104.0% | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| ROE | -55.4% | -55.4% | — | — | -1212.9% | -764.0% |
| ROA | -66.6% | -66.6% | -222.5% | -243.5% | -177.6% | -374.3% |
| ROIC | -658.2% | -658.2% | — | — | -8985.7% | — |
| ROCE | -78.6% | -78.6% | -1142.2% | -622.7% | -235.6% | -760.2% |
KMTS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $238M exceeds total debt of $44M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Debt / Equity | 0.22 | 0.22 | — | — | 12.94 | 0.12 |
| Debt / EBITDA | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.94 | — | — | -0.85 | -1.38 |
| Net Debt / EBITDA | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — |
| Interest Coverage | -13.75 | -13.75 | -13.65 | -14.29 | -28.00 | — |
Net cash position: cash ($238M) exceeds total debt ($44M)
KMTS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
KESTRA MEDICAL TECHNOLOGIES, LTD.'s current ratio of 6.72x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 0.50x to 6.72x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Current Ratio | 6.72 | 6.72 | 0.45 | 0.50 | 3.96 | 1.54 |
| Quick Ratio | 6.55 | 6.55 | 0.35 | 0.44 | 3.96 | 1.54 |
| Cash Ratio | 6.26 | 6.26 | 0.25 | 0.40 | 3.68 | 1.43 |
| Asset Turnover | — | 0.20 | 0.61 | 0.20 | — | — |
| Inventory Turnover | 5.42 | 5.42 | 8.34 | 8.65 | — | — |
| Days Sales Outstanding | — | 49.31 | 26.22 | 101.08 | — | — |
KMTS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
KESTRA MEDICAL TECHNOLOGIES, LTD. returns 0.2% to shareholders annually primarily through dividends.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Dividend Yield | 0.2% | 0.1% | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.2% | 0.1% | — | — | — | — |
| Shares Outstanding | — | $50M | $50M | $50M | $50M | $50M |
Peer Comparison
Compare KMTS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 KMTSYou | $1B | -3.9 | — | — | 40.5% | -177.8% | -55.4% | -658.2% | — |
 MDT | $102B | 22.0 | 14.5 | 19.6 | 65.3% | 17.8% | 9.4% | 6.0% | 3.2 |
 ABT | $154B | 11.6 | 16.1 | 24.2 | 50.8% | 16.3% | 30.9% | 9.9% | 1.5 |
 BSX | $67B | 23.3 | 20.8 | 18.4 | 69.0% | 19.8% | 12.4% | 8.8% | 3.3 |
 EW | $50B | 47.7 | 26.8 | 37.7 | 78.1% | 27.0% | 10.5% | 15.5% | 0.4 |
 LIVN | $4B | -17.6 | 17.2 | 24.9 | 67.7% | 14.4% | -19.2% | 11.5% | 2.0 |
 NVCR | $2B | -11.7 | — | — | 74.5% | -23.5% | -38.9% | -16.4% | — |
 AVNS | $1B | -17.1 | — | 27.1 | 49.8% | -8.8% | -8.5% | -5.4% | — |
 IRTC | $3B | -75.3 | — | 99.6 | 70.6% | -4.9% | -36.6% | -5.2% | — |
 BEAT | $26M | -1.2 | — | — | — | — | -987.3% | — | — |
 TXN | $294B | 59.2 | 38.2 | 112.9 | 57.0% | 34.1% | 30.1% | 15.8% | 1.9 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 5 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
KMTS — Frequently Asked Questions
Quick answers to the most common questions about buying KMTS stock.
What is KESTRA MEDICAL TECHNOLOGIES, LTD.'s P/E ratio?
KESTRA MEDICAL TECHNOLOGIES, LTD.'s current P/E ratio is -3.9x. This places it at the 50th percentile of its historical range.
What is KESTRA MEDICAL TECHNOLOGIES, LTD.'s ROE?
KESTRA MEDICAL TECHNOLOGIES, LTD.'s return on equity (ROE) is -55.4%. The historical average is -55.4%.
Is KMTS stock overvalued?
Based on historical data, KESTRA MEDICAL TECHNOLOGIES, LTD. is trading at a P/E of -3.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What is KESTRA MEDICAL TECHNOLOGIES, LTD.'s dividend yield?
KESTRA MEDICAL TECHNOLOGIES, LTD.'s current dividend yield is 0.17%.
What are KESTRA MEDICAL TECHNOLOGIES, LTD.'s profit margins?
KESTRA MEDICAL TECHNOLOGIES, LTD. has 40.5% gross margin and -177.8% operating margin.